Same drug, two brains: NU670's final Unit 10 paper sets fluoxetine in a maturing adolescent brain beside an aging one, pairing each developmental claim with its evidence. Searches like "nu 670 unit 10 assignment example", "nu670 unit 10 sample" and "nu670 unit 10 example" land here.
What a finished NU670 Unit 10 developmental neuroscience paper looks like
Roughly eight pages in three parts. Its first part covers the developing brain: longitudinal MRI shows cortical gray matter thinning from back to front through adolescence, with prefrontal regions maturing last (Gogtay et al., 2004), and the paper links this to the imbalance model of adolescent risk-taking, labeled as a framework drawn from imaging and behavior. It then covers fluoxetine's FDA approval for pediatric depression, the 2004 boxed warning on suicidality, extended in 2007 to young adults through age 24, and the pooled trial analysis behind it (Hammad et al., 2006). Part two turns to aging: slower hepatic clearance and norfluoxetine's long half-life, hyponatremia through inappropriate antidiuretic hormone secretion, falls, and white matter hyperintensities associated with poorer response. Entries for SSRIs in the 2023 AGS Beers Criteria are cited. Part three reads the two stages against each other.
How a NU670 Unit 10 example is structured
A short introduction states the paper's claim: development changes both what a drug meets in the brain and how the body delivers it, and those changes run in opposite directions at the two ends of life. The adolescent and aging parts follow one template, developmental facts first, then pharmacokinetics, then observed clinical effects, then what remains unexplained, which turns the comparison in part three into a matter of reading across. Each developmental claim carries its evidence type in the sentence: longitudinal imaging, pooled randomized trials, observational cohorts, or animal work such as early-life fluoxetine exposure in mice producing lasting behavioral change (Ansorge et al., 2004). The paper is explicit that the mechanism behind the adolescent suicidality signal is unknown and that the imbalance model is a hypothesis about it. Composite details stay minimal and bracketed. The conclusion names questions the evidence cannot yet answer.
Opposite directions, one drug
The introduction frames the comparison: the adolescent brain is still building prefrontal control while the older brain is losing reserve. Setting that frame first lets each later observation land as part of a pattern rather than a separate fact.
Imaging that shows timing
Longitudinal MRI data on gray matter maturation are presented with their design, repeated scans of the same young people over years. The paper notes what such data show about timing and what they cannot show about function.
A warning without a mechanism
The adolescent suicidality signal is reported from pooled trials, with no completed suicides in those data. Its developmental cause is stated plainly as unknown, and every proposed mechanism is treated as a hypothesis.
Aging read through body and brain
Slower clearance, a very long-lived metabolite and altered sodium regulation change what fluoxetine does to an older body, while white matter change alters what it acts on. The paper keeps kinetic and neural explanations distinct.
What neither end explains
The conclusion lists open questions: why a minority of adolescents show activation, and whether vascular change causes poorer late-life response or merely accompanies it. Ending there matches the course's insistence on stated uncertainty.
Where marks go in NU670 Unit 10
When maturation and aging are described up front and play no part once fluoxetine enters, the comparison the prompt asked for goes unmade, and that omission costs more than any other. Explaining the adolescent suicidality warning with a confident developmental mechanism draws the most pointed comments, since every such account remains a hypothesis. Mouse findings on early-life exposure applied directly to teenagers, with no note of the difference in developmental timing, draw a deduction. Treating older adults only as slower metabolizers, with no attention to the aging brain itself, earns partial credit. Any line on whether the composite adolescent or older adult should take the drug, or at what amount, moves outside the assignment. Smaller deductions follow from misdating the boxed warning, from overstating Beers guidance as a prohibition, and from reviews cited in place of primary studies.
Get a NU670 Unit 10 example written to your instructions
Which drug and which two life stages does your NU670 Unit 10 prompt compare? Send those details and the rubric, or ask for a drug to be chosen. A free first paper follows those instructions and arrives within 24-48h, written to one template for both ages, with every developmental claim carrying the type of evidence behind it.
NU670 Unit 10 questions, answered
Why do adolescent and adult antidepressant trials give different results?
Partly unknown, which the paper can say. Proposed reasons include developmental differences in serotonergic and prefrontal systems, higher placebo response in younger participants, and differences in trial design. Present each as a candidate with its evidence rather than choosing one, since a clearly stated uncertainty usually earns more here than a confident guess.
How should the Beers Criteria be cited?
By year, with the specific entry and its stated rationale. The 2023 AGS Beers Criteria list SSRIs among drugs to use with caution because of hyponatremia risk and advise avoiding them in people with a history of falls unless safer alternatives are unavailable. Describe these as expert consensus guidance, not as rules that forbid use.
Can animal studies of early exposure be used?
Yes, with their timing explained. Mouse studies giving fluoxetine in early postnatal life correspond to earlier human development than adolescence, so they speak to vulnerability windows in general rather than to teenagers directly. Naming that mismatch shows the careful handling of animal evidence this course looks for.